Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium (APTE)

Sara Rafael Fernandez

Status and phase: Completed; Phase 2

Conditions: Infertility; Infertility, Female

Treatments: Drug: Plasma rich in growth factors (PRGF-Endoret)

Study type: Interventional

Funder types: Other

Identifiers

NCT03387501

APTE

Details and patient eligibility

About

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Enrollment: 13 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women who signed informed consent.
• Women who understand the Spanish language.
• Women under 42 years

Exclusion criteria

• Thrombopenia.
• Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
• Ovarian tumors.
• Benign uterine tumors require surgical treatment
• Local acute inflammatory diseases
• Patients with malignant tumors requiring chemotherapy.
• Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
• Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

13 participants in 1 patient group

PRGF

Experimental group

Description:

Plasma rich in growth factors (PRGF) administration

Treatment:

Drug: Plasma rich in growth factors (PRGF-Endoret)